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Abstract: Laser printer-emitted nanoparticles (PEPs) generated from toners during printing represent
one of the most common types of life cycle released particulate matter from nano-enabled products.
Toxicological assessment of PEPs is therefore important for occupational and consumer health
protection. Our group recently reported exposure to PEPs induces adverse cardiovascular responses
including hypertension and arrythmia via monitoring left ventricular pressure and electrocardiogram
in rats. This study employed genome-wide mRNA and miRNA profiling in rat lung and blood
integrated with metabolomics and lipidomics profiling in rat serum to identify biomarkers for
assessing PEPs-induced disease risks. Whole-body inhalation of PEPs perturbed transcriptional
activities associated with cardiovascular dysfunction, metabolic syndrome, and neural disorders at
every observed time point in both rat lung and blood during the 21 days of exposure. Furthermore,
the systematic analysis revealed PEPs-induced transcriptomic changes linking to other disease risks
in rats, including diabetes, congenital defects, auto-recessive disorders, physical deformation, and
carcinogenesis. The results were also confirmed with global metabolomics profiling in rat serum.
Among the validated metabolites and lipids, linoleic acid, arachidonic acid, docosahexanoic acid,
and histidine showed significant variation in PEPs-exposed rat serum. Overall, the identified
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PEPs-induced dysregulated genes, molecular pathways and functions, and miRNA-mediated
transcriptional activities provide important insights into the disease mechanisms. The discovered
important mRNAs, miRNAs, lipids and metabolites may serve as candidate biomarkers for future
occupational and medical surveillance studies. To the best of our knowledge, this is the first study
systematically integrating in vivo, transcriptomics, metabolomics, and lipidomics to assess PEPs
inhalation exposure-induced disease risks using a rat model.
Keywords: printer emitted nanoparticles; inhalation; transcriptomics; metabolomics; lipidomics;
biomarkers; nanotoxicity
1. Introduction
The unique physicochemical properties of engineered nanomaterials (ENMs) are being exploited
for use in a growing variety of commercial nano-enabled products (NEPs), including electronics,
cosmetics, agriculture and food, structural materials, as well as a wide variety of products for medical
applications [1–4]. Numerous in vitro and in vivo studies have investigated the possible adverse
effects of inhalation exposure to pristine ENMs during synthesis and handling [5–8]. However, human
exposure is not limited to pristine ENMs, but to a wide variety of particles released from NEPs
across their life cycle, including consumer use and disposal [9–12]. Indeed, the potential for exposure
from such life cycle particulate matter (LCPM) may exceed that of pristine engineered nanoparticles
(ENPs) [13]. All pristine materials are ENPs. LCPM is the term we introduced to explain that pristine
ENPs across their cycle and value chain can be released in the air but their properties differ due to their
transformations. For instance, an ENP which will be used in a nano-enabled paint will be released
during sanding and drilling, but the released LCPM will have different physico-chemical properties
compared to pristine ENP used in the paint. The same applies to the pristine metallic nanoparticles
used to formulate the toner of laser printers. When those ENPs are released in the air they will have
completely different physico-chemical properties and will include in their surface organic compounds
that are not there for the pristine ENPs. Moreover, the toxicological profiles of LCPM may differ greatly
from those of pristine ENPs [14,15]. Despite the potential for LCPM exposure, most nanotoxicology
studies have focused on pristine ENPs and thus, toxicological evaluation of LCPM has been limited.
The National Institute for Occupational Safety and Health (NIOSH) and the Environmental Protection
Agency (EPA) have, therefore, recommended life cycle analyses in their nanotechnology research
programs [16,17]. Most importantly, we need to develop integrated methodologies that can link real
world LCPM exposures to toxicology and diseases.
The rate at which production of new ENPs and incorporation into NEPs occurred has far exceeded
our ability to test all ENPs and LCPM released over the NEP life cycle using in vivo animal studies.
This study will focus on a specific real-world LCPM: laser printer-emitted particles (PEPs) generated
from nano-enabled toners which has been studied extensively by the authors and others over the
last decade [18,19]. In US alone, 23 million printers are produced annually, and over 160,000 workers
are employed in copier centers [20–28]. The new generation of toners contain ENPs, such as metals
and metal oxides, and that PEPs with mode sizes of 49–208 nm are released during printing at
concentrations of up to 1.3 million particles/cm3 [15]. There is growing evidence from both in vitro
cellular and in vivo animal studies of significant bio-activity of PEPs, which points to potential adverse
health effects from inhalation exposure [15,28–36]. Our group recently suggested exposure to PEPs
increases cardiovascular risk by impairing ventricular performance and inducing hypertension and
arrhythmia [37]. Currently, there are no available biomarkers for assessing adverse cardiovascular
responses induced by PEPs exposure in susceptible individuals with long-term exposure.
Genomic/transcriptomic analysis has become a routine approach in biomedical research and
has increasing applications in toxicology [38,39]. However, this is not the case in nanotoxicology
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research. Gene expression analysis could aid mechanistic studies by evaluating the relevance of
signaling pathways representing significantly perturbed genes for treatment interventions [40–42].
Since miRNAs are more stable than mRNA, and can be obtained from minimally-invasive biological
samples, such as blood, they can provide more insight into identifying valuable diagnostic and predictive
biomarkers [43,44]. Integrated analysis of miRNA and mRNA could reveal post-transcriptional
functional involvements of the identified gene markers and provide novel biomarkers for worker
surveillance and targets for therapeutic interventions of cardiovascular disease or lung damage [45,46].
Schulte et al. [47] suggested that biomarkers of early responses are necessary for an optimal risk
surveillance program for workers in the nanotechnology field.
This study will address this research gap using a systematic, integrated approach combining in vivo,
metabolomic, lipidomic, and transcriptomic studies, to evaluate both pulmonary and cardiovascular
effects of PEPs exposure. Metabolomic profiles were sequentially assessed following exposure to PEPs
to reflect dynamic responses to any pathophysiological changes that may have occurred. Such an
approach provides a fresh opportunity for biomarker discovery to elucidate systemic changes occurring
following exposure to PEPs. Genome-scale profiles were performed in rat lung tissue and blood to
identify important gene signatures relevant to PEPs-induced adverse effects and potential mechanistic
pathways. The highly novel integrated in vivo and computational transcriptomic/metabolomic analyses
in this study will identify biomarkers of potential PEPs-induced adverse cardiopulmonary effects for
occupational/commercial risk surveillance, and reveal important insights into intervention strategies.
2. Results
2.1. Real-Time Animal Exposure Characterization
The animal exposure characterization data were presented in great detail in a recent publication by
the authors [48]. Table S1 summarized the real-time measurements of the mean particle diameter (nm),
particle number concentration (105 #/cm3), particle mass concentration (µg/m3), and count median
diameter (nm) of PEPs from laser printer B1 (Table S1 and Figure S1).
The total number concentration during all exposure sessions was approximately 4× 105–5× 105 #/cm3
with size distributions relatively constant across the 21-day exposure duration [48]. It is also worth
noting that as shown in previous studies by the authors, PEPs are a complex mixture of primarily
organic and elemental carbon, 1–3% metals (Cu, Ce, Cr, Ni, Fe, and Ti), and low and high molecular
weight PAHs [19,21]. Furthermore, tVOCs analysis showed VOCs to be present at relatively low
concentrations, with daily averages between 244.8 ± 164.2 parts per billion (ppb) and 363.2 ± 161.7 ppb.
The tVOC levels for this study were not measured but expected to be the same as in our previous studies.
2.2. mRNA/miRNA Profiling in PEPs-Exposed Rat Lung Tissues
There were 11,010 genes with measured expression in rat lung tissues. At each day of PEPs
exposure, genes with a differential expression of at least 1.5-fold change were identified. In a systematic
analysis of these genes, the top 5 most significantly (p < 0.05) enriched pathways across PEPs exposure
time points were listed in Table 1. The top 5 most significantly (p < 0.05) impacted biological processes,
molecular functions and diseases were included in Table S2. Top significant (p < 0.05) miRNA
down-regulators (otherwise notified) of these differentially expressed genes were listed in Table 2.
At day 1 of PEPs exposure, 190 differentially expressed genes were identified in rat lung tissues
compared with the control group exposed to HEPA-filtered air. There was perturbation in metabolism,
circadian regulation, redox reactions, and immune response, with disease implications in sleep disorder,
chemical carcinogenesis, and dysfunctional blood clotting in rat lung (Table 1 and Table S2). There
was no significant miRNA regulator of differentially expressed genes at 1 day of PEPs inhalation
(Table 2). It is noteworthy that numerous genes, including Cyp2c6v1, Cyp2c22, Cyp3a18, Cyp2b3,
Cyp2c13, Ugt2b35, and Adh7 in the chemical carcinogenesis pathway, were significantly (p < 0.05)
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changed from their normal expression levels (Table 1) in the PEPs-exposed rat lung on day 1, implying
potential tumorigenesis due to laser printer emission exposure.
Table 1. Top 5 significant (p < 0.05) KEGG pathways in PEPs-exposed rat lung tissues. The listed genes
had a fold change of at least 1.5 in rat lung tissues exposed to PEPs vs. HEPA-filtered air control group.




























Circadian Rhythm Nr1d1, Per2, Per3, Bh1he40 Arntl
Day 5
Viral Myocarditis RT1-Bb, Cycs, RT1-CE16,RT1-N1
Herpes Simplex Infection Pilra, RT1-Bb, Cycs, RT1-CE16,Ifit1, LOC100910669, RT1-N1
Antigen Processing and
Presentation Klrc3 RT1-Bb, RT1-CE16, RT1-N1
Cardiac Muscle
Contraction Tnnc1, Tnni3, Tnnt2, Cox6a2




Herpes Simplex Infection Ifit1, C5, RT1-CE16, Per2
Dilated Cardiomyopathy Tnnc1, RGD1565478
Viral Carcinogenesis Hist1h4m, RT1-CE16
Systemic Lupus
Erythematosus Hist1h4m, C5 RGD1565478
Day 21
Huntington’s Disease
Dnah5, Dnai2, Dnai1, Dnah12,
Dnah6, Dnali1, Dnah7, Dnah3,
Dnah11, Dnah14, Cox6a2, Dnah9
Hypertrophic
Cardiomyopathy
Tnnc1, Tnnt2, Myh6, Tnni3, Ryr2,
Actc1, Mybpc3, Ttn
Circadian Rhythm Cry1, Per2, Rorc, Rorb, Npas2
Cardiac Muscle
Contraction
Tnnc1, Tnnt2, Myh6, Tnni3, Ryr2,
Cox6a2, Actc1
Dilated Cardiomyopathy Tnnc1, Tnnt2, Myh6, Tnni3, Ryr2,Actc1, Mybpc3, Ttn
At day 5 of continuous PEPs inhalation, there were 112 differentially expressed genes in rat
lung tissues. Four miRNAs (rno-let-7e-5p, rno-miR-34c-5p, rno-miR-351-5p, and rno-miR-207)
were identified as significant (p < 0.05) down-regulators of all 112 genes differentially expressed
in PEPs-exposed rat lung tissues (Table 2). Exposure induced transcriptional perturbations in rat lung
associated with adverse cardiovascular and immune responses, such as viral myocarditis and antigen
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processing, Type I diabetes mellitus, negative regulation of ATP activity, mental retardation, muscle
movements, and skeletal defects (Table 1 and Table S2).
Table 2. Top identified miRNA targeting multiple differentially expressed genes in rat lung tissues.
Predicted miRNAs with a significant p-value (p < 0.05) in the enrichment analysis are listed. Genes
listed in the table were down-regulated by the corresponding miRNA unless otherwise specified with
an asterisk (*).
Exposure Time Point miRNA Differentially Expressed Target Genes
Day 1 − −
Day 5
rno-let-7e-5p Bpifa1, RGD1359158, RT1-Bb, Fcrl2, Myom2
rno-miR-34c-5p C6, Cd177, Akr1c12, Csrp3
rno-miR-351-5p RGD1566006, Tnnc1, Ahrr, Cox6a2
rno-let-7b-5p C6, Mb, Cd177, Myom2
Day 9 rno-miR-15b-5p Gper1, Sln, Stox1, Styk1, LOC102550375
rno-miR-322-5p (rno-miR-322-3p) Gper1, Olr384, Zfp623, Sln, Styk1
Day 21
rno-miR-135a-5p
RGD1359158, Scgb3a1, Enpp3, Pon1, Tspan1,
Cerkl, Efhd1, Cfap45, Spa17, Aoc1, Ffar4, Ccdc153,
Wfdc21, Olr404, Fv1, Ces2g, Rgs16*
rno-miR-29c-3p Fabp3, Olr297, Rsph4a, Eln, Tspan1, Spa17,Tsnaxip1, Kif24, Ffar4, Npepo, Gpr37
rno-miR-143-3p Bpifa1, Chst9, Pon1, Rarres1, Lrrc23, Bpifa5, Ribc2,RGD1304810, Saxo2, Efhb, Dnali1, Npepo, Dnah11
rno-miR-151-3p (rno-miR-151-5p) Tnnc1, Sln, Fabp3, Srl, Tmc5, Rtn4ip1, Cfap206,Ttc21a, Saxo2, Hrc, Foxa3, Riiad1, Cd8a *
* Up-regulated genes.
Of 100 genes differentially expressed in the rat lung at day 9 of PEPs exposure, 3 miRNAs
(rno-miR-15b-5p, rno-miR-322-5p, and rno-miR-322-3p) significantly (p < 0.05) down-regulated the
expression of genes listed in Table 2. PEPs exposure, on Day 9, affected stem cell division, immune
response, viral carcinogenesis, and metabolism, with implications in cardiovascular disease and neural
disorders manifested by transcriptional perturbations in the PEPs-exposed rat lung (Table 1 and
Table S2).
At day 21 of continuous PEPs exposure, 369 genes were differentially expressed in the rat lung.
Among 38 significant (p < 0.05) miRNA regulators of these differentially expressed genes, the top 5
miRNAs were rno-miR-135a-5p, rno-miR-29c-3p, rno-miR-143-3p, rno-miR-151-3p, and rno-miR-151-5p
(Table 2). Continuous PEPs inhalation at day 21 dysregulated ATP activity and metabolic pathways in
rat lung, and was associated with Huntington’s disease, cardiovascular disease, and an autosomal
recessive disorder, primary ciliary dyskinesia (Table 1 and Table S2).
In summary, continuous whole-body inhalation of PEPs affected biological processes and molecular
functions of the rat lung related to cardiovascular disease, immune response, metabolism, type I
diabetes mellitus, and neural disorders from days 1–21. In particular, cardiovascular dysfunction,
metabolic syndrome, and neural disorders were significantly higher in PEPs-exposed rats at every
time point (day 1, 5, 9, and 21). These results are concordant with the cardiovascular pathological data
(manuscript in review [37]) and toxicology data [48] collected from the same animal study.
2.3. mRNA/miRNA Profiling in PEPs-Exposed Rat Blood
There were 14,791 genes with measured expression in rat blood. Differentially expressed genes
with a fold change of at least 1.5 were first identified for each time point. Base on the analysis of these
differentially expressed genes, the top 5 most significantly (p < 0.05) enriched pathways were included
in Table 3. The top 5 most affected (p < 0.05) biological processes, molecular functions, and diseases
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were listed in Table S3. The top significant (p < 0.05) miRNA down-regulators of these differentially
expressed genes in rat blood were listed in Table 4 for each PEPs-exposure time point.
Table 3. Top 5 significant (p < 0.05) KEGG pathways in PEPs-exposed blood. The listed genes had a
fold change of at least 1.5 in rat blood exposed to PEPs vs. HEPA-filtered air control group. Genes with
a statistically significant (p < 0.05) differential expression are highlighted in bold.
Exposure




Platelet Activation Gp5, Gp1bb, Gp9, Gp1ba, Itga2b, Vwf,P2rx1, P2ry12, Itgb3, Gucy1a3, Ptgs1 F2r, Mapk13
ECM-Receptor Interaction Col6a5, Gp5, Gp1bb, Gp9, Gp1ba, Sv2a,Itga2b, Vwf, Itgb3, Itga6
Hematopoietic Cell Lineage Gp5, Gp1bb, Gp9, Gp1ba,Itga2b, Cd9, Itgb3
Legionellosis Naip6, Naip5 Casp9, Cycs
Olfactory Transduction
Olr220, Olr259, Olr712, Olr352, Olr120,
Olr1206, Olr1073, Olr472, Olr756, Olr1433,
Olr613, Olr920, Olr1143, Olr126, Olr1093,
Olr1l, Olr60, Olr1274, LOC500460, Olr214,
Olr67, Olr816, Olr1385, Olr1229,
Olr298, Olr380




Olr1422, Olr748, Olr480, Olr130, Olr252,
Olr1369, Olr448, Olr611, Olr1401, Olr569,
Olr199, Olr1471, Olr140, Olr1230, Olr808,
Olr119, Olr826, Olr499, Olr230, Olr168,
Olr1539, Olr1192, Olr1332, Olr255, Olr1619
Gng13, Olr240, Olr339, Olr1460,




Plcb1, Gngt2, Xcr1, Gng13, Ccr1,
Cx3cr1, Ccr1l1
Biosynthesis of Unsaturated
Fatty Acid Hacd1 Acaa1a, Acot3
Protein Processing in













Sodium Reabsorption Kras, LOC298795, Ins2, Fxyd2
Glycosylphosphatidylinositol
(GPI)-Anchor Biosynthesis Pigw, Pigo Pigz










Olr168, Olr1619, Olr1002, Olr300
Ribosome Rpl30, Rsl24d1, Rpl15, Rpl18, Rpl37a
Collecting Duct Acid
Secretion Atp6v0e1, Atp6v1g3
Histidine Metabolism Hdc, Maob
mRNA Surveillance
Pathway Magoh, Sap18
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Table 3. Cont.
Exposure




























Metabolism Alox12e, Ptges3l1, Hpgds
Type I Diabetes Mellitus Cpe Gzmb
Ferroptosis Hmox1
Mineral Absorption Hmox1
Vitamin B6 Metabolism RGD1566085
Table 4. Top identified miRNA targeting multiple differentially expressed genes in PEPs-exposed rat
blood. Predicted miRNAs with a significant p-value (p < 0.05) in the enrichment analysis are listed.
Genes listed in the table were down-regulated by the corresponding miRNA unless otherwise specified
with an asterisk (*).
Exposure Time Point miRNA Differentially Expressed Target Genes
Day 1 − −
Day 5
rno-miR-349 Try10, Ppm1h, Nags, Kif13b, Atg101, P2ry2, Slc16a3, Trmt44
rno-miR-200a-3p Ca5b, Pi16, Krtap3-3, Rpl10l, Olr1196, Tmem220, Slc16a3,Cx3cr1, Ndufa2 *
rno-miR-129-5p Adam6, Sulf2, Slc26a6, Thtpa, LOC500124, Tnfsf10, Mrgprf,Gria3 *
rno-miR-31a-5p Ca5b, Supt4h1, Rpl13, Kif13b, Ell3, Doc2g, Cdca3,LOC500124, Tp53rk, Sec11c *, Olr748 *
Day 9 rno-miR-365-3p Pclaf, Olr721, Rpl13, Cd160, Glod5, Olr713
Day 13 rno-miR-378a-3p(rno-miR-378a-5p)
Fbln1, Doc2a, Andpro, LOC102546864, Hist2h2ab,
Tmem222, Oas1a, Atp6v0e1 *
Day 17 − −
Day 21
rno-miR-872-5p Plekhb1, Gzmb, Trappc2l, Npl, Lrrc61, Hmox1, Hpgds
rno-miR-124-3p RGD1359158, Clic2, Trappc2l, Rtn4ip1, Supt4h1
rno-miR-30e-5p (rno-miR-30a-5p) Fv1, Ces1c, Alox12e, Ldhb, Gzmb
* Up-regulated genes.
There were 477 differentially expressed genes identified in rat blood at day 1 of PEPs exposure.
These differentially expressed genes were significantly (p < 0.05) associated with the integrity of blood
vessel wall (including vascular vessel), cellular adhesion, migration, differentiation, proliferation, and
apoptosis, hematopoietic stem cell lineage, neuromuscular function, and metabolism. The implicated
diseases (p < 0.05) included pneumophila, abnormal bleeding and adverse cardiovascular responses
(Table 3 and Table S3). There was no significant (p < 0.05) miRNA regulator of these differentially
expressed genes (Table 4).
Int. J. Mol. Sci. 2019, 20, 6348 8 of 32
Of 384 genes differentially expressed in rat blood at day 5 of PEPs inhalation, significant
(p < 0.05) miRNAs regulating these differentially expressed genes were rno-miR-349, rno-miR-200a-3p,
rno-miR-129-5p, and rno-miR-31a-5p (Table 4). In brief, 5 days of continuous inhalation of PEPs had a
manifested impact on metabolism, inflammatory responses, and various neural disorders in rat blood
(Table 3 and Table S3). It is noteworthy that tumor necrosis binding pathway was dysregulated with
differentially expressed genes Tnfsf13, Erap1, Tnfsf10, and Nucb2 (p < 0.05; Table S3). MiR-200a-3p,
essential in epithelial-mesenchymal transition and metastasis [49], was a significant (p < 0.05) regulator
of numerous differentially expressed genes in rat blood (Table 4). Meningioma, a tumor that arises
from the membranes surrounding brain and spinal cord, was among a top significant disease with
differentially expressed genes Klf4 and Smarce1l (Table S3) associated with PEPs inhalation in rat blood.
These results indicate considerable PEPs-induced tumorigenic transcriptional dysregulation, and are
consistent with the activated pathways of chemical carcinogenesis at day 1 and viral carcinogenesis at
day 9 in rat lung (Table 1).
At day 9 of continuous PEPs inhalation, 358 genes were differentially expressed in rat blood.
Perturbed regulation of these genes in rat blood affected metabolism and inflammatory responses, and
had implications in genetic defects of neural disorders and mental retardation, autoimmune diseases,
and viral carcinogenesis (p < 0.05; Table 3 and Table S3). Prominently, viral carcinogenesis pathway
was activated in both rat lung and blood at day 9 of PEPs exposure (Table 1; Table 3). The significant
(p < 0.05) miRNA regulating these differentially expressed genes was rno-miR-365-3p (Table 4).
At day 13 of PEPs exposure, 291 genes were differentially expressed in rat blood. The alteration
of these genes was associated with RNA regulation, ATP activities, metabolism, cardiovascular
and inflammatory responses, with disease implications in transient neonatal diabetes mellitus and
multiple congenital disorders and defects, including postaxial polydactyly, non-syndromic X-linked
mental retardation, spondyloepiphyseal dysplasia with congenital joint dislocations, and hereditary
hypotrichosis with recurrent skin vesicles syndrome (p < 0.05; Table 3 and Table S3). Rno-miR-378a-3p
and rno-miR-378a-5p were the significant (p < 0.05) regulators of differentially expressed genes in rat
blood at day 13 (Table 4).
There were 271 genes differentially expressed in rat blood at day 17 of PEPs exposure. These genes
were over-represented in immune responses, redox reactions, metabolism, GDP/GTP activities, and
had implications in type I diabetes mellitus, arthritis, physical disability (Hansen’s disease; leprosis),
inflammatory lung disease and skin reaction (p < 0.05; Table 3 and Table S3). No significant miRNA
regulator was identified for these 271 differentially expressed genes (Table 4).
A total of 98 differentially expressed genes were identified in rat blood at day 21 of PEPs exposure.
These genes were enriched in metabolism, immune responses, ATP activities, and were associated with
type I diabetes mellitus and multiple autosomal recessive diseases and abnormalities, including
fronto-otopalatodigital osteodysplasia, FLNB-related disorders, spondylocarpotarsal synostosis
syndrome, limb-girdle muscular dystrophy type 2A, and Bart-Pumphrey syndrome (p < 0.05; Table 3
and Table S3). Rno-miR-872-5p, rno-miR-124-3p, and rno-miR-30e-5p (rno-miR-30a-5p) were identified
as significant down-regulators of the differentially expressed genes (Table 4).
2.4. Global Untargeted Profiling of Metabolomics and Lipidomics in Rat Serum
Of the predictive metabolites and lipids, those numbered as 59, 63, 131, 54, 124 and 140 can be
mapped with greater than 90% isotypes similarity from Human Metabolome Database (HMDB) and
Lipid Maps Database that were differentially expressed (p < 0.05) between HEPA and PEPs exposed
rats at day 1, 5, 9, 13, 17 and 21 (Table S4) respectively. Two unknown metabolites were significantly
elevated in the PEPs exposed group across all 6 time points (Figure 1A,B).
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Figure 1. Normalized abundance of compounds 1 and 2 across the exposure days between PEPs exposed and HEPA control rats. Both compounds 1 and 2 are significantly 
(p < 0.05) elevated in the serum of PEPs exposed rats across the six time points. (A) Compound 1 (0.75_181.1299 m/z) abundance; (B) Compound 2 (2.63_443.2326 m/z) 
abundance. 
Figure 1. Normalized abundance of compounds 1 and 2 across the exposure days bet ee c ntrol rats. Both compounds 1 and 2 are
significantly (p < 0.05) elevated in the serum of PEPs exposed ra s across the six time points. (A) Compound 1 (0.75_181.1299 m/z) abundance; (B) Compound 2
(2.63_443.2326 m/z) abundance.
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There were significant enrichments of metabolites and lipids involved in glycerophospholipid,
linoleic acid, biotin, biosynthesis of unsaturated fatty acids, alpha-linolenic acid, sphingolipid and
histidine metabolism across the various PEP exposure days (Table 5 and Table S5). Collectively, these
pathways associated with a range of established inflammatory, cardiovascular and metabolic disease
states like glycogenosis type VII, hypertension, dengue fever, gestational diabetes mellitus, Hartnup
disease and histidinemia (Table 6 and Table S6).
Table 5. Top 5 associated pathways and their respective compounds across the different exposure days
in pathway analysis. Pathways that are significantly different (p < 0.05) between PEPs-exposed and
HEPA control rat serum are highlighted bold. Compounds that are significantly different (p < 0.05) in





Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate
Acyl Ester; CDP-Ethanolamine; 1-Phosphatidyl-d-myo-inositol;
Glycerylphosphorylethanolamine; Glycerophosphocholine;
Phosphatidyl-N-methylethanolamine; Phosphatidylglycerophosphate; Cardiolipin
Linoleic Acid Metabolism Linoleic acid; Phosphatidylcholine; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME;13-l-Hydroperoxylinoleic acid
Biotin Metabolism Biotin; Biotinyl-5′-AMP; Biocytin; Holo-[carboxylase]; l-Lysine
Pyrimidine Metabolism Uridine; Uracil
Alpha-Linolenic Acid
Metabolism
Thioredoxin; Uridine 5′-diphosphate; l-Glutamine; Carbamoylphosphate;
4,5-Dihydroorotic acid; Orotidylic acid; RNA; Uridine triphosphate; Uridine
5′-monophosphate; Uridine; Dihydrouracil; Ureidopropionic acid; Cytidine
triphosphate; CDP; Cytidine monophosphate; Cytidine; Thioredoxin disulfide;
dCDP; dCTP; dCMP; Deoxycytidine; Deoxyuridine triphosphate; dUDP; dUMP;
Deoxyuridine; Thymidine 5′-triphosphate; dTDP; 5-Thymidylic acid; Thymidine;
Dihydrothymine; Ureidoisobutyric acid; P1,P4-Bis(5′-uridyl) tetraphosphate;
Ureidosuccinic acid; Phosphoribosyl pyrophosphate; Orotic acid; Uracil;





Icosenoyl-CoA; Tetracosanoyl-CoA ; Docosanoyl-CoA;
(7Z,10Z,13Z,16Z)-Docosatetraenoyl-CoA; (11Z,14Z)-Icosadienoyl-CoA;
(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoyl-CoA; (11Z,14Z,17Z)-Icosatrienoyl-CoA;




13,16-Docosadienoic acid; Nervonic acid; Erucic acid; Icosenoic acid; Tetracosanoic
acid; Behenic acid; 7,10,13,16-Docosatetraenoic acid; Icosadienoic acid;
Clupanodonic acid; Icosatrienoic acid; Palmitic acid; Stearic acid; Arachidic acid;
Oleic acid; Linoleic acid; Arachidonic acid; 8,11,14-Eicosatrienoic acid;
Gamma-Linolenic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid;
Eicosapentaenoic acid; Alpha-Linolenic acid
Linoleic Acid Metabolism Linoleic acid; Phosphatidylcholine; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME;13-L-Hydroperoxylinoleic acid
Alpha-Linolenic Acid
Metabolism






Phenylpyruvic acid; l-Phenylalanine; l-Tyrosine; 4-Hydroxyphenylpyruvic acid
Glycerophospholipid
Metabolism
Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate
Acyl Ester; CDP-Ethanolamine; 1-Phosphatidyl-d-myo-inositol;
Glycerylphosphorylethanolamine; Glycerophosphocholine;
Phosphatidyl-N-methylethanolamine; Phosphatidylglycerophosphate; Cardiolipin







Icosenoyl-CoA; Tetracosanoyl-CoA ; Docosanoyl-CoA;
(7Z,10Z,13Z,16Z)-Docosatetraenoyl-CoA; (11Z,14Z)-Icosadienoyl-CoA;
(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoyl-CoA; (11Z,14Z,17Z)-Icosatrienoyl-CoA;




13,16-Docosadienoic acid; Nervonic acid; Erucic acid; Icosenoic acid; Tetracosanoic
acid; Behenic acid; 7,10,13,16-Docosatetraenoic acid; Icosadienoic acid;
Clupanodonic acid; Icosatrienoic acid; Palmitic acid; Stearic acid; Arachidic acid;
Oleic acid; Linoleic acid; Arachidonic acid; 8,11,14-Eicosatrienoic acid;
Gamma-Linolenic acid; (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid;
Eicosapentaenoic acid; Alpha-Linolenic acid
Glycerophospholipid
Metabolism
Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate




Vitamin A; Retinal; B-Carotene; 11-cis-Retinal; Retinyl ester; 9-cis-Retinol;
11-cis-Retinol; Retinoic acid; 9-cis-Retinal; Retinyl palmitate;
All-trans-13,14-dihydroretinol; 11-cis-Retinyl palmitate; all-trans-4-Hydroxyretinoic
acid; all-trans-18-Hydroxyretinoic acid; all-trans-5,6-Epoxyretinoic acid; 9-cis-Retinoic
acid; Retinoyl b-glucuronide
Tryptophan Metabolism
l-Tryptophan; Melatonin; N-Acetylserotonin; Serotonin; 5-Hydroxyindoleacetic
acid; 5-Hydroxykynurenamine; 5-Hydroxykynurenine; 5-Hydroxy-l-tryptophan;
l-Formylkynurenine; Acetoacetyl-CoA; (S)-3-Hydroxybutanoyl-CoA;
Crotonoyl-CoA; Glutaryl-CoA; Oxoadipic acid; 2-Amino-3-carboxymuconic acid
semialdehyde; 3-Hydroxyanthranilic acid; l-Kynurenine; Formylanthranilic acid;
l-3-Hydroxykynurenine; 3-Hydroxykynurenamine; Indoleacetaldehyde;
5-Hydroxy-N-formylkynurenine; 5-Hydroxyindoleacetaldehyde; Tryptamine;
Indoleacrylic acid; Acetyl-N-formyl-5-methoxykynurenamine; 6-Hydroxymelatonin;
Formyl-5-hydroxykynurenamine; 5-Methoxyindoleacetate; 4,6-Dihydroxyquinoline;
Acetyl-CoA; 2-Aminomuconic acid semialdehyde; 2-Aminobenzoic acid;
l-Tryptophanyl-tRNA(Trp); Cinnavalininate;
4-(2-Amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid;
4-(2-Aminophenyl)-2,4-dioxobutanoic acid; 4,8-Dihydroxyquinoline; Indoleacetic
acid; N-Methylserotonin; N-Methyltryptamine




Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate
Acyl Ester; CDP-Ethanolamine; 1-Phosphatidyl-d-myo-inositol;
Glycerylphosphorylethanolamine; Glycerophosphocholine;
Phosphatidyl-N-methylethanolamine; Phosphatidylglycerophosphate; Cardiolipin
Linoleic Acid Metabolism Linoleic acid; Phosphatidylcholine; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME;13-l-Hydroperoxylinoleic acid
Alpha-Linolenic Acid
Metabolism






(Ino(acyl)-P)1; Dolichyl phosphate d-mannose; (GlcN)1 (Ino(acyl)-P)1 (Man)3 (EtN)1
(P)1; Phosphatidylethanolamine; (GlcNAc)1 (Ino-P)1; (GlcN)1 (Ino(acyl)-P)1
(Man)2 (EtN)1 (P)1; (GlcN)1 (Ino(acyl)-P)1 (Man)1; (GlcN)1 (Ino-P)1; Palmityl-CoA;
(GlcN)1 (Ino(acyl)-P)1 (Man)1 (EtN)1 (P)1; (GlcN)1 (Ino(acyl)-P)1 (Man)3 (EtN)2 (P)2;
6-(alpha-d-glucosaminyl)-1D-myo-inositol
Sphingolipid Metabolism
Sphinganine; Ceramide 1-phosphate; Sphingosine 1-phosphate; Sphinganine
1-phosphate; Dihydroceramide; Phytoceramide; SM; Ceramide; Palmityl-CoA;
l-Serine; 3-Dehydrosphinganine; Galabiosylceramide; Galactosylceramide; GM4;
Lactosylceramide; Glucosylceramide; Sphingosine; 3-O-Sulfogalactosylceramide
(d18:1/24:0); Phytosphingosine; Digalactosylceramidesulfate;
O-Phosphoethanolamine




Linoleic Acid Metabolism Linoleic acid; Phosphatidylcholine; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME;13-l-Hydroperoxylinoleic acid
Glycerophospholipid
Metabolism
Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate




Sphinganine; Ceramide 1-phosphate; Sphingosine 1-phosphate; Sphinganine
1-phosphate; Dihydroceramide; Phytoceramide; SM; Ceramide; Palmityl-CoA;
l-Serine; 3-Dehydrosphinganine; Galabiosylceramide; Galactosylceramide; GM4;
Lactosylceramide; Glucosylceramide; Sphingosine; 3-O-Sulfogalactosylceramide
(d18:1/24:0); Phytosphingosine; Digalactosylceramidesulfate;
O-Phosphoethanolamine
Biotin Metabolism Biotin; Biotinyl-5′-AMP; Biocytin; Holo-[carboxylase]; l-Lysine
Alpha-Linolenic Acid
Metabolism




Linoleic Acid Metabolism Linoleic acid; Phosphatidylcholine; 9,10-Epoxyoctadecenoic acid; 12,13-EpOME;13-l-Hydroperoxylinoleic acid
Glycerophospholipid
Metabolism
Phosphatidylethanolamine; Phosphatidylcholine; Dihydroxyacetone phosphate;
LysoPC(18:1(9Z)); 1,2-Diacyl-sn-glycerol; Citicoline; Phosphorylcholine; Choline;
Acetylcholine ; O-Phosphoethanolamine; Ethanolamine; PA(16:0/16:0); Acyl-CoA;
1-Acyl-sn-glycerol 3-phosphate; CDP-diacylglycerol; Glycerol 3-phosphate;
1-Acyl-sn-glycero-3-phosphoethanolamine;
2-Acyl-sn-glycero-3-phosphoethanolamine; 2-Acyl-sn-glycero-3-phosphocholine;
CDP-glycerol; PS(16:0/16:0); Phosphatidylglycerol; Dihydroxyacetone Phosphate




l-Glutamic acid; 4-Imidazolone-5-propionic acid; Urocanic acid; l-Histidine;
Imidazole-4-acetaldehyde; 1-Methylhistamine; Methylimidazole acetaldehyde;
Histamine; Carnosine; N-Formyl-l-aspartate; Formiminoglutamic acid;




Icosenoyl-CoA; Tetracosanoyl-CoA ; Docosanoyl-CoA;
(7Z,10Z,13Z,16Z)-Docosatetraenoyl-CoA; (11Z,14Z)-Icosadienoyl-CoA;
(7Z,10Z,13Z,16Z,19Z)-Docosapentaenoyl-CoA; (11Z,14Z,17Z)-Icosatrienoyl-CoA;




13,16-Docosadienoic acid; Nervonic acid; Erucic acid; Icosenoic acid; Tetracosanoic
acid; Behenic acid; 7,10,13,16-Docosatetraenoic acid; Icosadienoic acid; Clupanodonic
acid; Icosatrienoic acid; Palmitic acid; Stearic acid; Arachidic acid; Oleic acid;
Linoleic acid; Arachidonic acid; 8,11,14-Eicosatrienoic acid; Gamma-Linolenic acid;
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid; Eicosapentaenoic acid;
Alpha-Linolenic acid
Sphingolipid Metabolism
Sphinganine; Ceramide 1-phosphate; Sphingosine 1-phosphate; Sphinganine
1-phosphate; Dihydroceramide; Phytoceramide; SM; Ceramide; Palmityl-CoA;
L-Serine; 3-Dehydrosphinganine; Galabiosylceramide; Galactosylceramide; GM4;
Lactosylceramide; Glucosylceramide; Sphingosine; 3-O-Sulfogalactosylceramide
(d18:1/24:0); Phytosphingosine; Digalactosylceramidesulfate;
O-Phosphoethanolamine
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Table 6. Disease pathway analysis showing the top 5 disease associated pathways and their respective
compounds involved across the exposure days. Disease pathways that are significantly different
(p < 0.05) between PEPs-exposed and HEPA control rat serum are highlighted bold. Compounds that
are significantly different (p < 0.05) in PEPs-exposed rat serum from HEPA control are in red text.
Disease Pathway Analysis Compound
Day 1
Glycogenosis, Type VII. Tarui Disease Bilirubin; Uric acid
Lesch-Nyhan Syndrome Hypoxanthine; Uric acid; Uridine; Xanthine;Folic acid
Liver Disease due to Cystic Fibrosis
Chenodeoxycholic acid; Cholic acid;
Deoxycholic acid; Glycocholic acid; Lithocholic
acid; Ursodeoxycholic acid
2-Hydroxyglutaric Academia (l) l-Lysine; l-2-Hydroxyglutaric acid





Angiotensin II; Angiotensin III; Alpha-Linolenic
acid; Arachidonic acid; Docosahexaenoic acid;
Eicosapentaenoic acid; Linoleic acid;
Dimethyl-l-arginine
Dengue Fever l-Alanine; l-Histidine; l-Phenylalanine
Gestational Diabetes Mellitus Arachidonic acid; Docosahexaenoic acid;O-Phosphoethanolamine
Histidinemia Histamine; l-Histidine
Inflammatory Diseases l-Phenylalanine; l-Tyrosine
Day 9
Hartnup disease l-Tryptophan; 5-Hydroxyindoleacetic acid
Carnitine Palmitoyl Transferase Deficiency (II)
d-Glucose; l-Palmitoylcarnitine; Ammonia;
Oleoylcarnitine; Myoglobin; Long chain acyl
carnitines; Oleoylcarnitine; l-Acetylcarnitine
Spastic Ataxia 5-Hydroxyindoleacetic acid; Homovanillic acid;
l-Tryptophan; Thiamine; Vanylglycol
Progressive Familial Intrahepatic Cholestasis
24,25-Dihydroxyvitamin D; 25-Hydroxyvitamin
D2; Vitamin A; Bilirubin; Alpha-Tocopherol;
Cholesterol





Cystic Fibrosis 24,25-Dihydroxyvitamin D; d-Glucose; VitaminA; Alpha-Tocopherol
Progressive Familial Intrahepatic Cholestasis
24,25-Dihydroxyvitamin D; 25-Hydroxyvitamin
D2; Vitamin A; Bilirubin; Alpha-Tocopherol;
Cholesterol
Day 17
2-Hydroxyglutaric Academia (l) l-Lysine; l-2-Hydroxyglutaric acid
Histidinemia Histamine; l-Histidine
Hyperlysinemia I, Familial Hyperpipecolatemia Pipecolic acid; l-Lysine
2,4-Dienoyl-CoA Reductase Deficiency l-Lysine; Decadienoylcarnitine (C10:2);
l-Carnitine
Dengue Fever l-Alanine; l-Histidine; l-Phenylalanine
Day 21
Histidinemia Histamine; l-Histidine
Alpha-1-Antitrypsin Deficiency (AATD) alpha-1-Antitrypsin; Glycocholic acid
Dengue Fever l-Alanine; l-Histidine; l-Phenylalanine
Gestational Diabetes Mellitus Arachidonic acid; Docosahexaenoic acid;O-Phosphoethanolamine
Nephrotic Syndrome 25-Hydroxyvitamin D2; Calcidiol; Histamine
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2.5. Validation and Quantification of Linoleic Acid, Palmitic Acid and Histidine Pathways in Rat Serum
Given the observation that the linoleic acid pathway, which has an important inflammatory role,
was enriched at days 5, 17 and 21, we next validated and quantified linoleic acid, arachidonic acid,
docosahexanoic acid (DHA) and palmitic acid using commercial standards. Histidine and histamine
were also validated and quantified given their direct roles in the sensitization and human allergy
response. Linoleic acid gradually increased significantly (p < 0.014) at Day 9 of PEPs exposure, after
which it dramatically declined by Day 13. At Day 21, both PEPs and HEPA-exposed samples returned
back to baseline (normal) levels (Figure 3A). Arachidonic acid, a downstream metabolite of linoleic acid,
was similarly elevated at day 9 of PEPs exposure (p < 0.0077) and again significantly reduced at day 13
(p = 0.022) and day 17 (p = 0.0065) before returning to baseline by Day 21 (Figure 3B). DHA shared a
similar profile to linoleic and arachidonic acid (Figure 3C). Palmitic acid, a metabolite feeding into the
linoleic acid pathway through conversation to oleic acid, although not significant, was observed to
be at lower concentrations in PEPs exposed rat serum compared to HEPA at day 1 through 17 before
returning to baseline compared to control (Figure 3D). Histidine quantification is significantly lowered
in day 5 (p = 0.016) and day 17 (p = 0.033) of continuous PEPs inhalation (Figure 3A), and although
non-significant, a similar trend was observed with histamine (Figure 3B), a downstream product
of histidine.
Combined with the transcriptomic profiles of PEPs-induced mRNA expression changes in rat
blood and lung, upstream and downstream genes regulating the identified metabolites were depicted
in Figure 3; Figure 3. Genes removed from the initial filtering analysis were not included in the figures,
indicating no detectable variation across the samples. Heatmaps of expression of genes regulating
linoleic acid, arachidonic acid, docosahexanoic acid (DHA) and palmitic acid in both rat lung and
blood across PEPs exposure time points were shown in Figure 3E–H. Time-series mRNA expression of
genes regulating histidine and histamine was shown in Figure 3C,D, respectively.
In summary, continuous PEPs inhalation dysregulated genes involved in metabolism, inflammatory/
immune responses, and neural functions at every time point (day 1, 5, 9, 13, 17, and 21) in rat blood.
The mRNA perturbation observed across various metabolic pathways was consistent with our global
metabolomics results in which it was observed to have changed significantly across the corresponding
time-points particularly for linoleic and arachidonic acid metabolism, each of which has established
inflammatory roles. Pathogenesis of adverse cardiovascular response and disease was remarkable at
days 1, 13, and 21 in rat blood. Similarly, an association in hypertension, a risk factor for cardiovascular
diseases, was observed at day 5, when increases in linoleic acid pathway activity were established.
These results confirm those from the rat lung and the cardiovascular pathological data (manuscript
in review [37]). There was significant transcriptional aberration associated with autosomal-recessive
disorders in rat blood after continuous PEPs inhalation at days 5, 9 and 21. Genes relevant to various
congenital disorders and defects were significantly dysregulated in rat blood at days 13 and 21 of PEPs
exposure. PEPs-induced carcinogenic transcriptional perturbation was evident in rat blood at days 5
and 9, consistent with the results from rat lung at days 1 and 9. Continuous PEPs inhalation induced
dysregulation of genes and pathways of diabetes at days 13, 17, and 21. Dysregulation of metabolites
associated with diabetes were similarly observed at day 5. These results in rat blood suggested linkage
of PEPs exposure to cardiopulmonary risk, metabolic syndrome, diabetes, neural disorders, congenital
defects, auto-recessive disorders, physical deformation, and carcinogenesis.
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Figure 2. Quantification of linoleic acid, arachidonic acid, docosahexanoic acid (DHA) and palmitic acid in PEPs and HEPA control inhalation rat serums and heatmaps of 
genes regulating these metabolites in rat blood and lung. Fatty acids that were quantified (bold) are illustrated in the pathway. Palmitic acid, linoleic acid, arachidonic acid 
plays a role in pro-inflammatory response (red box) while anti-inflammatory are shown in blue box. (A) Linoleic acid, (B) Arachidonic acid, (C) Docosahexanoic acid and 
(D) Palmitic acid. *—Adjusted p-value < 0.05. Heatmaps depict log fold change (LogFC) of genes regulating Linoleic acid, Arachidonic acid, Docosahexaenoic acid (DHA), 
and Palmitic acid in both rat blood and lung samples at each day. (E) Genes regulating linoleic Acid, (F) Genes regulating arachidonic acid, (G) Genes regulating 
docosahexaenoic acid, (H) Genes regulating palmitic acid in rat blood and lung samples. *—0.01 < p-value < 0.05, **—p-value < 0.01. 
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Figure 3. Quantification of histidine and histamine in PEPs and HEPA control inhalation rat serums and expression of genes regulating histidine and histamine in both rat 
blood and lung samples. Metabolites that were quantified (bold) are illustrated in the pathway. Histidine and histamine plays a role in pro-inflammatory response (A) 
Histidine and (B) Histamine. *—Adjusted p-value < 0.05. Log fold change (LogFC) of mRNA expression of genes regulating Histidine and Histamine in both blood and 
lung samples at each day. (C) Genes regulating Histidine both rat blood and lung samples, (D) Genes regulating Histamine both rat blood and lung samples. *—0.01 < p-
value < 0.05, **—p-value < 0.01. Genes removed from the initial filtering analysis were not included in the figure, indicating no detectable variation across the samples. 
 
Figure 3. Quantification of histidine and histamine in PEPs and HEPA control inhalation rat serums and expression of genes regulating histidine and histamine in both
rat blood and lung samples. Metabolites that were quantified (bold) are illustrated in the pathway. Histidine and histamine plays a role in pro-inflammatory response
(A) Histidine and (B) Histamine. *—Adjusted p-value < 0.05. Log fold change (LogFC) of mRNA expression of genes regulating Histidine and Histamine in both
blood and lung samples at each day. (C) Genes regulating Histidine both rat blood and lung samples, (D) Genes regulating Histamine both rat blood and lung
samples. *—0.01 < p-value < 0.05, **—p-value < 0.01. Genes remov d from the initial filteri g nalysis were not included in the figure, indicating o detectable
variation across the samples.
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3. Discussion
PEPs generated from nano-enabled toners are one of the most common types of LCPM released
from various nano-enabled products in consumer and occupational use scenarios. The toxicological
assessment of PEPs is of utmost importance for worker and consumer health protection. PEPs are
deemed highly bioactive in in-vitro and in-vivo studies and may impose significant potential adverse
health effects, as previously reported by our group and others [15,28–36]. This study utilized a highly
novel and integrated, genome-wide mRNA and miRNA profiling in rat lung and blood combined
with metabolomics and lipidomics profiling in rat serum to assess PEPs-induced cardiopulmonary risk
and other disease implications. The identified PEPs-induced dysregulated genes, pathways, biological
processes, molecular functions, and miRNA-mediated transcriptional activities provide important
insights into the disease mechanisms and are in agreement with in-vitro and in-vivo toxicological
studies of PEPs. Furthermore, the identified important mRNA/miRNA, lipids and metabolites may
serve as candidate biomarkers for future occupational and medical surveillance studies.
The respiratory system is the primary route of exposure to airborne particulate matters (PM) via
inhalation. Epidemiological studies indicated there is a correlation between inhalation of particles
from ambient air and an increased incidence of cardiovascular diseases [50,51]. Numerous in vivo and
in vitro studies demonstrated that inhalation exposure to PM causes not only pulmonary damages, but
induces adverse cardiovascular effects [52–54]. Several mechanisms may be involved in the induction of
cardiovascular effects upon inhalation exposure of particulates, particularly those less than PM0.1. First,
the translocation of particulates from respiratory system into the blood circulatory through penetrating
the air-blood barrier [55]. Second, inhalation of particulates induces pulmonary inflammation,
which may mediate a systemic oxidative/inflammatory response that leads to cardiovascular effects [56].
Third, inhalation exposure may trigger neurogenic regulated mechanisms to modulate cardiovascular
function [57]. Therefore, evaluation of the changes in gene expression of lung and blood following
inhalation exposure to particulates in printer emissions may provide a transcriptomic profiling tool to
assess cardiovascular toxicity as well as potential toxicity in other tissue organs. The findings from this
study will provide guidance for designing future specific disease model-based studies of PEPs-induced
toxicity in a particular tissue organ.
Our group reported that PEPs exposure caused no damage in the histological and chemiluminescence
analysis of lung and heart tissues in the in vivo animal studies [48]. However, PEPs exposure elevated
sympathetic influence, impaired ventricular performance and repolarization, and caused hypertension
and arrhythmia, suggesting increased cardiovascular risk [37]. The results of the global transcriptomic
profiling in this study confirmed these pathological data. No significant perturbation in molecular
pathways or processes linking to pulmonary diseases was identified in rat lung or blood following
PEPs inhalation. In contrast, PEPs inhalation exposure dysregulated genes and pathways involved
in cardiovascular malfunction at every observed time point in rat lung and several time points in
rat blood. At day 1 of PEPs exposure, Fgb was up-regulated (p < 0.05) in rat lung, with implications
in inherited thrombophilia, afibrinogenemia and dysfibrinogenemia (Table S2). At day 5 of PEPs
inhalation, RT1-Bb, associated with dilated cardiomyopathy, viral myocarditis, and Type I diabetes
mellitus, was down-regulated (p < 0.05) in rat lung (Table 1 and Table S2). At day 9 of PEPs exposure,
Scn5a was up-regulated (p < 0.05) in rat lung, indicating implications in familial idiopathic ventricular
fibrillation, dilated cardiomyopathy, progressive cardiac conduction defect, and progressive familial
heart block (Table S2). At day 13 of PEPs inhalation, genes involved in the regulation of vascular
endothelial growth factor production, Noda1, Sulf2, and Ccr2, were down-regulated (p < 0.05) in rat
blood (Table S2). At day 21 of PEPs inhalation, Tnnc1 was down-regulated (p < 0.05) in rat lung,
with involvements in cardiac muscle contraction and tissue morphogenesis, dilated cardiomyopathy,
and hypertrophic cardiomyopathy (Table 1 and Table S2). Myh6, associated with left ventricular
noncompaction, was down-regulated (p < 0.05) in rat lung (Table S2). These results are concordant
with the cardiovascular pathology data (manuscript in review [37]).
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PEPs inhalation exposure also dysregulated ATP activities, sodium and manganese metabolism,
and redox functions in rat lung and blood with implications in cardiovascular dysfunctions and
blood pressure abnormality. In PEPs exposed rat blood, up-regulation of Atp6v0e1 at days 1 and 13,
down-regulation of Atp5g1 and Atp6v1f at day 1, and up-regulation of Atp6v1g3 at day 13 were evident
(p < 0.05; Table S3). Five days of continuous PEPs inhalation up-regulated Slco3a1 and LOC685081 and
down-regulated Slco5a1, which are associated with sodium-independent organic anion transmembrane
transporter activity (p < 0.05; Table S3). Perturbed aldosterone-regulated sodium reabsorption with
up-regulation of Kras was identified in rat blood at day 9 of PEPs inhalation (p < 0.05; Table 3).
Manganese ion binding dysfunction with up-regulation of Ppef2 and down-regulation of Idi1 was
identified in rat lung at day 9 of PEPs exposure (p < 0.05; Table S2). These molecular dysfunctions
of sodium and manganese absorption are relevant to high blood pressure, and confirm the observed
blood pressure variation in PEPs-exposed rats (manuscript in review [37]). Remarkable disrupted
redox functions were identified in rat lung and blood following PEPs inhalation. At day 1, altered
oxidoreductase activity and arachidonic acid monooxygenase activity with up-regulation of Cyp2c22,
Cyp3a18, Cyp2b3, Cyp2a1, Cyp2c6v1, Cyp4a3 and Cyp3a23/3a1 were identified in rat lung (p < 0.05;
Table S2). At 17 days of continuous PEPs inhalation, negative regulation of oxidoreductase activity
was ranked a top changed biological process in rat blood with up-regulation of Cav1 and Hp (p < 0.05;
Table S3).
The whole genome analysis mirrored the global metabolomics profiles following whole-body PEPs
inhalation. Global metabolomics illustrated significant (p < 0.05) activation of glycerophospholipid
metabolism, linoleic acid metabolism, and biosynthesis of unsaturated fatty acids upon PEPs exposure.
In transcriptomics analysis, linoleic acid metabolism pathway was among top 5 significant (p < 0.05)
pathways in rat lung at Day 1 of PEPs inhalation, with up-regulated genes Cyp2c6v1, Cyp2c22, and
Cyp3a18 (p < 0.05; Table 1). The up-regulation of these 3 genes was also involved in dysregulated steroid
hormone biosynthesis, epoxygenase P450 pathway, and endopeptidase activity (Table S2). At Day 5 of
PEPs inhalation, biosynthesis of unsaturated fatty acid pathway was a top altered pathway in rat blood,
with up-regulation of Hacd1 and down-regulation of Acaa1a (p < 0.05; Table 3). In addition, negative
regulation of fatty acid metabolic process was evident in rat blood at Day 17, with up-regulation of
Insig2 (p < 0.05; Table S3).
Activation of the innate immune systems via extracellular and/or intracellular receptors, such
as Fc, mannose or Toll-like receptors, can lead to the synthesis of inflammatory lipid mediators
like eicosanoids [58,59]. This is in agreement with in-vitro PEPs studies by the authors [60]. These
lipid mediators are derived from arachidonic acid, anω-6 polyunsaturated fatty acid that mammals
directly incorporate through diet or by synthesis from linoleic acid [61]. Prostanoids, a major class of
eicosanoids, modulates the inflammatory and immune responses [59]. Prostaglandin (PG) E2 is by
far the best characterized prostanoid from an immunomodulatoty perspective. Although cytokines
are key regulators of immunity, eicosanoids, including PGE2, PGD2, leukotriene (LT) B4, including
LTC4, also differentially affect the immune cells by modulating cytokine release, cell differentiation,
survival, migration, antigen presentation, and apoptosis. By acting on various aspects of immune
function and inflammation, such lipid mediators act as key regulators of the crosstalk between innate
and adaptive immunity. Upon early exposure to PEPs (Days 1–9), an up-regulation in linoleic acid,
arachidonic acid and DHA metabolism was detected, suggestive of an innate immunity response
to PEPs. Particle-generated reactive oxygen species (ROS) can further influence signaling pathways
leading to activation of the arachidonic acid cascade [62–64]. Studies of titanium oxide nanoparticle
inhalation shows significantly impairment of the endothelium-dependent vasoreactivity in coronary
arterioles due to increases in microvascular ROS [65]. Similarly, in a previous in-vitro PEPs study
by the authors, it was shown that small airway epithelial cells exposure induces cellular effects on
human microvascular endothelial cells in an alveolar-capillary co-culture model [28]. The addition of
prostanoid formation further contributed to this dysfunction. Deregulation in coronary microvascular
function may contribute to cardiac events associated with exposure to particles in this size range [65].
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Similar reports have also describe the impact on the arachidonic acid pathway by combustion-derived
particles and air pollution [62,66].
Arachidonic acid may also be processed through non-enzymatic reactions. The four double bonds
of arachidonic acid are readily oxygenated to form bioactive molecules. Therefore, oxidative stress
and/or exposure to ROS and reactive nitrogen species (RNS) results in the oxidation of arachidonic acid,
leading to generation of isoprostanes and nitroeicosatetraenoic acids [67], which in turn inhibits COX1,
and causes platelet aggregation, vasoconstriction, smooth muscle cell proliferation, and cardiomyocyte
hypertrophy [67]. Arachidonic acid enters numerous metabolic pathways that interconnect lipid
metabolism with immunity and, therefore, has widespread effect.
DHA possesses anti-inflammatory functions [68]. Resolvins, whose functional roles involve
promoting restoration of normal cellular function following inflammation after tissue damage, are
a metabolic by-product of omega-3 fatty acid [69,70]. High DHA levels associate with linoleic and
arachidonic acid, suggesting an association with a resolving inflammatory response following PEPs
inhalation. Inflammation peaked at Day 9 and was suppressed from Day 13 to Day 17 followed by
high DHA expression which returned to baseline by Day 21 (Figure 3C).
Histidine is the precursor of histamine production. Metabolomic change in both is, therefore,
of interest due to their role in allergen-related sensitization and inflammation [71]. Despite this,
a significant decrease in histidine levels, but not histamine levels, was observed in our metabolomic
profiles, suggesting PEPs may have minimal roles in inciting the allergic response. Prior studies have
shown that L-histidine exhibits antioxidant capabilities, such as scavenging free radicals and chelating
divalent metal ions, hence its use to manage oxidative stress [72–74]. The physiological effects of
histidine include inhibition of pro-inflammatory biomarkers [74]. In vivo and in vitro studies illustrate
that administration of histidine lowers the levels of pro-inflammatory markers, such as interleukin 8,
interleukin 6, C-reactive protein and tumor necrosis factor alpha [75–77]. This indicates that histidine
does more than merely scavenge ROS but directly influences pro-inflammatory cytokines [75–77].
Mechanisms are likely associated with its potential to increase the amino acid pool and the antioxidant
status of cells [78]. Histidine levels are low in patients with heart failure and are correlated with B-type
natriuretic peptide, left ventricle ejection fraction, left ventricle end-diastolic volume index, inferior
vena cava diameter and the ratio of early diastolic velocity of the mitral inflow to mitral annulus,
respectively [79]. L-histidine is an effective inhibitor of spontaneous platelet aggregation and platelet
TXB2 generation and l-histidine intake reduces spontaneous platelet aggregation [80]. Such change
likely contributes to ROS attenuation in tissues and alleviate clinical symptoms while protecting against
intestinal, nervous, and cardiovascular damage.
4. Materials and Methods
4.1. Whole-Body Inhalation Exposure of Animals
The details of animal exposure and PM characterization were described by the authors in a recent
study [48]. In summary, Figure S1 (adapted from Pirela et al. [48]) outlines the Printer Exposure
Generation System (PEGS) used for the animal exposure. The PEPs-exposed group consisted of
Sprague Dawley rats housed in individual cages and exposed via whole-body inhalation to the
PEPs and gaseous pollutants of laser printer B1 using the PEGS described in detail in a previous
publication [48]. The printer was used to generate PEPs by printing a 5%-page coverage monochrome
document using standardized settings [15]. The laser printer B1 was selected based on exposure and
toxicological profiles reported in our previous studies [15]. In parallel, another group of animals was
exposed to high-efficiency particulate air (HEPA)-filtered air. The system was configured for twelve
chambers (one animal per chamber), each equipped with a port for aerosol delivery and temperature
and humidity measurement, and a gas sampling port.
Animals were placed in their chambers for 1–5 h for 5 days prior to the exposures to ensure they
gradually acclimated to the exposure chambers. The following week, animals were exposed to either
Int. J. Mol. Sci. 2019, 20, 6348 24 of 32
PEPs or the room HEPA-filtered air 5 h/day for up to 21 consecutive days. The exposure duration of
21 days, as well as the sacrifice time points (Day 1, 5, 9, 13, 17, and 21), were chosen as sub-chronic
exposure periods to provide several delivered doses to the lung and identify any signs of toxicity in
the cardiovascular or respiratory systems.
4.2. Animal Exposure Characterization (PEPs and Gaseous Co-Pollutants)
Real-Time Measurements
The particle number concentration, size distribution, temperature, relative humidity and total
volatile organic compounds (tVOC) levels were measured in real time in one of the 12 animal inhalation
exposure chambers throughout the exposure durations. A scanning mobility particle sizer (SMPS Model
3080, TSI Inc., Shoreview, MN, USA) was also used for measuring particle number concentration and
size distribution (ranging from 2.5 to 210 nm) in the chamber. Real-time particle number concentration
as a function of size collected by the SMPS was used to estimate the mass size distribution assuming
spherical particles and the density of carbon. Real-time tVOC levels were also monitored using a tVOC
monitor (Graywolf Sensing Solutions, Shelton, CT, USA). All the realtime instruments were calibrated,
and background tests were performed at the beginning of each sampling experiment. No significant
variation in the temperature (◦C) and relative humidity (%) in the inhalation animal chambers was
observed throughout the exposure period [48].
It is worth noting that a comprehensive chemical analysis of PEPs was performed by the authors
and described in detail in previous publications [19,21,48]. In summary, PEPs possess a complex
mixture of metals (1–33%) and primarily various organic compounds including polycyclic aromatic
hydrocarbon (PAHs; 0.0067%) and other compounds such as elemental carbon (1–3%), organic carbon
(42–89%). It is also worth noting that in a recent publication by the authors [19], it was documented that
there are synergistic interactions of catalytic metallic nanoparticles with gaseous sVOCs co-pollutants
which result in the formation of high molecular and carcinogenic PAHs on the surface of the PEPs.
4.3. Animals
One hundred thirty-four healthy, male, 9-week-old Sprague-Dawley rats, weighing an average
of 300 g, were purchased from Taconic Farms Inc. (Hudson, NY, USA). The rats were allowed to
acclimatize for 1 week before the studies were initiated. Baseline data was collected for 1 week before
the exposures occurred. The rats were maintained on a 12-h light/dark cycle and food and water were
provided ad libitum. Upon arrival, animals were randomly assigned a unique identification number,
which determines the exposure group for the animal. There were two treatment groups: (a) Control
group: high-efficiency particulate air (HEPA) filtered air, and (b) PEPs exposure group. All the animals
were treated humanely in accordance with the guiding principles on the Use of Animals in Toxicology
and the Animal Care and Use Committee of Harvard University (Ethical permit No. 04623, 2015).
4.4. Whole Blood and Lung Tissue Collection
At the completion of the exposure periods, the animals in each group were anaesthetized with
an intraperitoneal injection of a lethal dose (200 mg/kg) of pentobarbital sodium (Anthony Products
Co., Arcadia, CA, USA) and sacrificed by exsanguination, followed by whole blood and lung tissue
collection. Blood was collected in microfuge tubes pre-loaded with RNAlater and inverted 10 times and
transferred to−20 ◦C or−80 ◦C for storage. The samples were extracted according to the manufacturer’s
instructions or transferred to −80 ◦C for long term storage. The lung tissue was removed, placed in
liquid nitrogen, and stored at −80 ◦C.
4.5. RNA Isolation
Total RNA from frozen lung tissue was extracted using the RNeasy kit, with simultaneous
on-column digestion of DNA during RNA purification according to the manufacturer’s instructions
Int. J. Mol. Sci. 2019, 20, 6348 25 of 32
(Qiagen, Hilden, Germany). Total RNA isolation from whole blood (stored in RNAlater) was carried
out using RiboPure-Blood kit, followed by DNA removal treatment as described by the manufacturer
(LifeTechnologies, Carlsbad, CA, USA). Concentration and purity of RNA were quantified by the
A 260 nm/A 280 nm and A 260 nm/A 230 nm ratios using a NanoDrop ND-100 spectrophotometer
(Thermo Scientific lnc., Waltham, MA, USA). Samples were stored at −80 ◦C until shipment to the
University of Michigan for further processing and analysis.
4.6. mRNA and miRNA Microarray Profiling
Global mRNA expression profiles were generated with Rat Gene ST 2.1 plates at the University of
Michigan Microarray Facility using an Affymetrix Plus kit (Thermo Fisher Scientific Inc., Waltham,
MA, USA). Global miRNA expression profiles were generated with Rat GeneChip miRNA4.1 plates
with the same total RNA samples using a FlashTag kit. cDNA was synthesized from 500 ng total RNA,
amplified, fragmented, and biotinylated using a GeneChip WT PLUS Reagent kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA) according to manufacturer’s instructions. cDNA was then prepared
for hybridization with reagents from the Affymetrix GeneTitan Hybridization, Wash, and Stain Kit
for WT Array Plates. For hybridization, 2.76 µg was hybridized to the Affymetrix Rat Gene ST
2.1 Arrays, which were then washed, stained, and scanned using the GeneTitan Multi-Channel
Instrument according to Affymetrix’s User Guide for Expression Array Plates (P/N 702933 Rev. 2,
2013). Data were analyzed using the Limma, Oligo, and Affy Bioconductor packages implemented
in the open source R statistical environment. The robust multi-array average was used to normalize
the data and fit log2-transformed expression values. The raw microarray data were processed using
a robust multi-array average (RMA) method, and expression values were log2 transformed, with a
principal component analysis used as the final quality control step to visualize mRNA expression values.
The analysis was performed with the oligo package of Bioconductor in the R statistical environment.
The mRNA and miRNA expression profiles in rat lung and blood are available at the National Center
for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) with accession number
GSE127951 (with Sub-Series GSE127945, GSE127947, GSE127949, and GSE127950).
4.7. mRNA and miRNA Data Analysis
Affymetrix Transcriptome Analysis Console (TAC) software was used in miRNA and mRNA data
analysis. The microarray data were analyzed with weighted linear models and Bayes methods designed
specifically for microarray analysis [81]. Samples were also weighted based on a gene-by-gene update
algorithm designed to downweight chips that are deemed less reproducible [82]. Probe sets that had
a variance less than 0.05 were removed from further analysis. For mRNA data, only the probe sets
listed as “main” by Affymetrix were included for further pathway analysis, which excluded internal
controls and un-annotated genes. Probe sets with a fold change of 1.5 or greater were selected. p-Values
were adjusted for multiple comparisons using the false discovery rate (FDR) with Benjamini and
Hochberg tests.
4.8. Pathway, Gene Ontology, and Disease Analysis
Significant differentially expressed genes in PEPs exposed vs. HEPA-filtered air exposed rat lung
and blood were analyzed with iPathwayGuide (Adviata; Plymouth, MI, USA). These genes were
obtained using a threshold of 1 for statistical significance (p-value) and a log fold change of expression
with the absolute value of at least 0.58. The significance is represented in terms of the negative log
(base 10) of the p-value. These data were analyzed in the context of pathways obtained from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) database (Release 84.0 + /10–26 October 17) [83], gene
ontologies (GO) from the Gene Ontology Consortium database (6 November 2017) [84], miRNAs from
the miRBase (Release 21) and MICROCOSM (MicroCosm Targets Version 5) databases [85], and diseases
from the KEGG database (Release 84.0 + /10–26 October 17) [83]. The top 5 pathways were ranked in
terms of the two types of evidence computed by iPathwayGuide: over-representation on the x-axis
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(pORA) and the total pathway accumulation on the y-axis (pAcc). The two types of evidence, pORA
and pAcc, were combined into one final pathway score by calculating a p-value using Fisher’s method.
This p-value was then corrected for multiple comparisons using FDR or Bonferroni corrections.
4.9. Prediction of Active miRNAs
The prediction of active miRNAs [86] is based on the enrichment of differentially downregulated
target genes of the miRNAs. iPathwayGuide calculates the probability of observing a greater number
of differentially downregulated target genes for a given miRNA just by chance. This p-value was
computed using the hypergeometric distribution.
4.10. Lipid and Metabolite Profiling of Rat Serum
4.10.1. Sample Processing
Plasma (100 µL) and 400 µL of lipid/internal standard in isopropanol or acetonitrile were mixed
and incubated at 4 ◦C, with constant agitation at 1400 rpm for 2 h following centrifugation at 4 ◦C at
4500 rpm for 10 min. Supernatants were then collected for analysis [87].
4.10.2. Metabolite Quantification
One hundred microliters of serum were mixed with 200 µL of methanol-water (50:50 v/v) by
vortexing for 30 s. Following this, the mixture was incubated at 4 ◦C for 1 h and added to 200 µL
chloroform. Following vigorously vortexing (30 s) and centrifugation (14,000 rpm for 10 min at 4 ◦C),
proteins were precipitated. The organic and aqueous phases were next collected separately and dried
using vacuum centrifugation. The aqueous phase was then reconstituted in 200 µL of mobile phase E:F
(25:75 v/v, mobile phase E-30 mM ammonium formate in water and mobile phase F-30 mM ammonium
formate in 85:15 ACN: Water) and used for histamine and histidine analysis. The organic phase was
reconstituted in 100 µL ethanol for fatty acid analysis.
4.10.3. Histamine and Histidine Analysis
LC-MS/MS histamine and histidine analysis was performed using an ACQUITY UPLC system
(Waters, Milford, MA, USA) coupled to a Xevo TQ-MS system (Waters, Milford, MA, USA). Sample
(10 µL) were separated using A Waters ACQUITY BEH Amide (1.7 µM; 2.1 × 150 mM) at 40 ◦C in ESI
Positive mode for the aqueous phase containing histamine and histidine with eleution gradient using
mobile phases C and D (flow rate 0.4 mL/min) at 75% D linearly decreasing to 45% for 2 min and held
for 1 min before equilibrating the system for the next injection. For mass spectrometry, we used a
capillary voltage of 3.4 kV, desolvation temperature 400 ◦C, cone gas flow 150 L/h, desolvation gas
flow 800 L/h and a source temperature of 150 ◦C for analysis. Corresponding parameters for histamine
and histidine analysis were 2.5 kV, 450 ◦C, 0 L/h, 900 L/h, and 150 ◦C, respectively. MassLynx and
TargetLynx were used for data acquisition quantification respectively. Statistical analysis was carried
out using 2-way ANOVA followed by post-hoc multiple correction using FDR [88]. Details of lipid and
metabolite profiling were included in Supplementary File.
5. Conclusions
The current study is in agreement with other in vivo and in vitro studies, linking exposure
to nanoparticles to transcriptomic alterations associated with cardiovascular and inflammatory
diseases [5,24,30,35,60,89,90]. In addition to cardiovascular disease and metabolic syndrome,
continuous PEPs inhalation induced gene expression changes associated with neural disorders
in both rat lung and blood at every observed time point. Our group plan to validate the identified
genes and metabolites in rat heart tissues as well as blood samples from occupational workers in our
ongoing and future studies. Furthermore, the systematic analysis suggested PEPs exposure induced
transcriptional aberrations associated with other diseases in rats, including diabetes, congenital
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defects, auto-recessive disorders, physical deformation, and carcinogenesis. These findings provide
guidance for designing future in vivo studies using a disease-specific animal model for assessing
PEPs exposure-induced toxicity in a particular tissue organ. This study provides evidence for future
biomarker-based surveillance and mechanistic studies of PEPs-induced diseases. This study is novel
and to our knowledge, the first to integrate in vivo, transcriptomics, metabolomics, and lipidomics to
assess PEPs inhalation exposure-induced disease risks using a rat model.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/24/
6348/s1. Figure S1: Printer Exposure Generation System (PEGS). Table S1: Real-time particle characterization
from the whole-body PEPs exposure for 1, 5, 9, 13, 17, or 21 days. Table S2: Top significant (p < 0.05) biological
processes, molecular functions, and diseases in PEPs-exposed rat lung tissue in gene ontology analysis. Table S3:
Top significant (p < 0.05) biological processes, molecular functions, and diseases in PEPs-exposed rat blood in
gene ontology analysis. Table S4: Top significant (p < 0.05) predictive metabolites and lipids in PEPs-exposed
rat serum across the different days. Table S5: Pathway analysis were carried out using MetaboAnalyst software
using Hypergeometric Test for over-representative analysis and the Relative-betweeness Centrality for pathway
topology with Rattus norvegicus pathway library; Table S6: Diseases pathway enrichment analysis were carried
out using MetaboAnalyst software using human disease-associated metabolite sets which consist of a library
contains 344 metabolite sets reported in human blood.
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